Table A2.

Nonprotocol Cancer Therapy Received After Disease Progression

Therapy	Gefitinib		Placebo		Total No. of Patients*
	No. of Patients	%	No. of Patients	%
All patients	119	53.9	102	46.1	221
Hormonal therapy	0	0	1	1.0	1
Chemotherapy	59	49.6	48	47.1	107
Immunotherapy	0	0	1	1.0	1
EGFR inhibitor	16	13.4	19	18.6	35
BRM	4	3.4	2	2.0	6
HDC/autologous stem-cell transplantation	0	0	0	0	0
Radiation therapy	59	49.6	53	52.0	112
Surgery	15	12.6	18	17.6	33
Other therapy	10	8.4	15	14.7	25

Abbreviations: BRM, biologic response modifier; HDC, high-dose chemotherapy.

^*Four patient deaths were attributable to lung cancer without documented disease progression.